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376Objective: Remote ischemic preconditioning protects the myocardium from ischemia/reperfusion injury. We
recently identified protection by remote ischemic preconditioning to be associated with the activation of signal
transducer and activator of transcription 5 in left ventricular biopsy specimens of patients undergoing coronary
artery bypass grafting during isoflurane anesthesia. Because remote ischemic preconditioning did not protect the
heart during propofol anesthesia, we hypothesized that propofol anesthesia interferes with signal transducer and
activator of transcription 5 activation.
Methods: In a randomized, single-blind, placebo-controlled, prospective study, we analyzed an array of estab-
lished cardioprotective proteins during propofol anesthesia with or without remote ischemic preconditioning in
24 nondiabetic patients with 3-vessel coronary artery disease.
Results: Remote ischemic preconditioning (n ¼ 12) compared with no remote ischemic preconditioning
(n ¼ 12) failed to decrease the area under the troponin I time curve (273  184 ng/mL 3 72 hours vs
365  301 ng/mL 3 72 hours; P ¼ .374). Although phosphorylation of several protein kinases was increased
from baseline to reperfusion, signal transducer and activator of transcription 5 phosphorylation was not in-
creased and was not different between the remote ischemic preconditioning and no remote ischemic precondi-
tioning groups.
Conclusions: Remote ischemic preconditioning during propofol anesthesia did not evoke either signal trans-
ducer and activator of transcription 5 activation or cardioprotection, implying interaction of propofol with car-
dioprotective signaling upstream of signal transducer and activator of transcription 5. (J Thorac Cardiovasc Surg
2014;147:376-82)In classic ischemic preconditioning, defined by the protec-
tion mediated by brief episodes of ischemia/reperfusion,
a whole array of trigger and mediator molecules are in-
volved. For many of these molecules, pharmacologic re-
cruitment has been attempted.1 In addition to volatile
anesthetics, opioids, the vasopressor phenylephrine, adeno-
sine, and bradykinin have all been reported to evoke cardi-
oprotection.1 Remote ischemic preconditioning (RIPC),2,3
an attractive alternate method to classic ischemic
preconditioning for decreasing perioperative myocardial
damage, can also protect the human myocardium from
ischemia/reperfusion injury, as evidenced in patients
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The Journal of Thoracic and Cardiovascular Surg(CABG)4-6 or percutaneous coronary interventions.7,8 The
lack of protection found in several recent studies9-11
possibly relates to the anesthetic regimens used.12 We re-
cently reported decreased postoperative troponin I concen-
trations after RIPC only in patients undergoing CABG with
isoflurane but not in those who received propofol
anesthesia.13
The signal transduction of cardioprotection by RIPC, in-
cluding the transmission of the protective signal from the
distant organ and the intracellular pathways in cardiomyo-
cytes, is still unclear.We recently observed cardioprotection
by RIPC in patients undergoing CABG with previous RIPC
under isoflurane anesthesia and identified an increase in ty-
rosine 694 phosphorylation of signal transducer and activa-
tor of transcription (STAT)5 in left ventricular (LV) biopsy
specimens. STAT5 phosphorylation increased from base-
line to early reperfusion only in the patients who had under-
gone RIPC but not in the control patients. However, a causal
role for the observed STAT5 activation in cardioprotection
remains to be established.1,14
Because we observed protection by RIPC during isoflur-
ane, but not during propofol, anesthesia,13 we hypothesized
that propofol interferes with STAT5 activation, which was
shown to be activated in our previous study of cardioprotec-
tion by RIPC with isoflurane anesthesia. Accordingly, weery c January 2014
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
cTnI ¼ cardiac troponin I
cTnI
AUC
¼ area under the cTnI time curve
CPB ¼ cardiopulmonary bypass
LV ¼ left ventricular
RIPC ¼ remote ischemic preconditioning
STAT ¼ signal transducer and activator of
transcription
Kottenberg et al Acquired Cardiovascular Diseaseassessed in a randomized, single-blind, placebo-controlled,
prospective study, the effects of RIPC on STAT5 activation
and the serum troponin I concentrations in nondiabetic
patients undergoing CABG during propofol anesthesia.A
C
DMETHODS
Patients
The present study is part of an ongoing multiprotocol study
(ClinicalTrials.gov NCT01406678) addressing the effects and mechanisms
of RIPC and anesthesia on the cardiac troponin concentrations in patients
undergoing CABG. The institutional ethics committee approved the study,
and all patients provided written informed consent. The present cohort of
24 patients with 3-vessel coronary artery disease scheduled for CABG
(Table 1) was enrolled from June 2010 to December 2011. They were ran-
domized on the day of surgery to receive, under propofol/sufentanil anes-
thesia, either a RIPC protocol, consisting of repetitive left upper arm
ischemia (3 cycles of 5-minute cuff occlusion/5-minute reperfusion
each), or no RIPC (cuff uninflated). None of the patients, data, or samples
obtained in our previous studies of RIPC6,13,14 were included in the present
study.
All patients older than 18 years who were scheduled for elective, iso-
lated, first-time CABG for 3-vessel coronary artery disease were eligible
for the present study. The exclusion criteria were any type of diabetes mel-
litus (controlled by diet, oral drugs, or insulin), renal insufficiency (serum
creatinine> 2 mg/dL), peripheral vascular disease affecting the upper
limbs, acute coronary syndrome, acute or recent myocardial infarction, pre-
operative inotropic support before the induction of anesthesia, any type of
mechanical assist device, any condition potentially increasing the preoper-
ative cardiac troponin I (cTnI) level (eg, coronary interventions within the
previous 6 weeks), or any type of emergency surgery, combined CABG/
valve surgery, or any previous cardiac operations.
General Procedures
General anesthesia was induced by sufentanil (1 mg/kg, Sufenta;
Janssen-Cilag, Neuss, Germany) and etomidate (0.3 mg/kg, Hypnomidat;
Janssen-Cilag, Neuss, Germany), followed by rocuronium (0.6 mg/kg, Es-
meron; Organon Teknika, Oberschleibheim, Germany). Anesthesia was
maintained by continuous propofol infusion (0.07-0.15 mg/kg/min), with
additional sufentanil injected at the discretion of the responsible anesthesi-
ologist, as required. During extracorporal circulation, the patients contin-
ued to receive a propofol infusion.
Surgical revascularization was performed in all patients after a median
sternotomy. Hypothermic (30C-33C) cardiopulmonary bypass (CPB)
was instituted through an ascending aortic cannula and a 2-stage right atrial
cannula. After ascending aortic crossclamping, Bretschneider’s cardiople-
gia was introduced. After completion of the distal CABG anastomoses, theThe Journal of Thoracic and Caaortic crossclamp was released, and cardiac reperfusion ensued. After re-
warming the patient to 37C and separation from CPB, reversal of heparin
by protamine sulphate (3 mg/kg), and sternal closure, the patients were
transferred to the intensive care unit.13
Troponin I
To assess myocardial injury, cTnI was measured (Immunoassay Dimen-
sion Flex, Dade Behring GmbH, Marburg, Germany) at specified times for
72 hours after CABG in an accredited laboratory. The serum cTnI levels
were determined preoperatively and 1, 6, 12, 24, 48, and 72 hours postop-
eratively, and the area under the cTnI time curve (cTnI AUC) was
determined.
Western Blot Analyses
In each patient, transmural myocardial biopsy specimens of 2 to 5 mg
each were harvested using a Tru-Cut biopsy needle (Cardinal Health, Dub-
lin, Ohio) from the LV perfusion territory undergoing revascularization,
quickly frozen in liquid nitrogen, and stored at 80C until analysis.
The first biopsy specimen was taken at baseline before starting CPB, the
second after 10 minutes of myocardial reperfusion after aortic declamping.
Western blot analysis was performed with antibodies against the phosphor-
ylated and total forms of several established signaling proteins, including
protein kinase C, p38 mitogen-activated protein kinase, vasodilator-
stimulated phosphoprotein as a substrate of protein kinase G, endothelial
nitric oxide synthase, protein kinase B, extracellular-regulated kinase,
p70 ribosomal S6 protein kinase, glycogen synthase kinase 3b, STAT3,
and STAT5.14 The immunoreactivities of the phosphorylated proteins
were normalized to those of the respective total proteins.
Two aliquots of each sample were analyzed separately on 2 different
gels; therefore, these data can differ. The baseline and reperfusion samples
were compared within the no RIPC and RIPC group on 1 gel each, and the
baseline and reperfusion samples were compared between the no RIPC and
RIPC group on 1 gel each.
Study Protocol
After induction of anesthesia and endotracheal intubation, a standard
blood pressure cuff was inflated to 200 mm Hg (ie, always in excess of
the contralateral systolic radial artery pressure) for 5 minutes by a resident
assigned to the case and not involved in either randomization or data assess-
ment. As a control, a cuff was placed around the left upper arm but left un-
inflated. Three cycles of 5-minute left upper arm ischemia were separated
by 5-minute intervals of reperfusion by deflating the cuff. The RIPC proto-
col was always completed before the skin incision.
The data from 24 patients fulfilling the enrollment criteria were
analyzed in a single-blind, randomized protocol. Before the trial,
computer-generated randomization schedules were generated and placed
in sequentially numbered sealed envelopes. The laboratory personnel mea-
suring the troponin concentrations, patients, surgeons, echocardiographers,
and critical care teams were unaware of the treatments assigned for the
study duration. The resident anesthetists, who applied the protocol by in-
flating or not inflating the cuff could not be blind to the group assignment
but had no part in the data sampling or analysis.
Statistical Analysis
The patient characteristics and cTnI concentrations are expressed as
numbers, frequencies, or mean  standard deviation. The data were com-
pared using a 2-way analysis of variance and Student’s 2-sided t test for un-
paired samples. A chi-square test was used to compare the categorical
variables. The immunoreactivities on the same gels were compared by
paired (within groups) or unpaired (between groups) t tests.
The following a priori null hypothesis was tested using the cTnI AUC as
a primary and the STAT5 phosphorylation as a secondary criterion: (1) no
difference exists in cTnI AUC with and without RIPC during propofolrdiovascular Surgery c Volume 147, Number 1 377
TABLE 1. Demographic and perioperative data stratified by RIPC
Variable
Propofol anesthesia
P valueNo RIPC RIPC
Patient characteristics
Patients (n) 12 12
Age (y) 66  9 65  9 .42
Gender (n) .11
Male 11 10
Female 1 2
Weight (kg) 79  10 89  14 .30
Height (cm) 174  6 174  7 .24
Intraoperative variables
CPB time (min) 111  26 109  18 .82
Crossclamping time (min) 70  20 70  17 .54
Total anesthesia time (min) 326  61 348  54 .63
Adrenaline dosage (end of
surgery) (mg/kg/min)
0.05  0.02 0.05  0.02 .78
Sufentanil dosage (mg/kg/min) 0.01  0.002 0.01  0.003 .86
Neosynephrine dosage
(mg/kg/min)
0.03  0.02 0.02  0.02 .74
Volume of cardioplegia (mL) 1433  320 1525  122 .56
In-hospital mortality (n) 0 0 1.00
Risk factors and comorbidities (n)
Hypertension 10 11 .82
Hyperlipidemia 11 10 .33
Obesity 10 9 .28
Current smoker 6 5 .35
Antihypertensive medications (n)
b-Blocker 10 10 .79
Calcium channel blocker 1 6 .15
ACEI/ARB 10 8 .67
Diuretics 2 1 .83
Data are presented as numbers or mean standard deviation. RIPC, Remote ischemic
preconditioning; CPB, cardiopulmonary bypass; ACEI, angiotensin-converting
enzyme inhibitor; ARB, angiotensin receptor blocker.
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FIGURE 1. Time course of serum cardiac troponin I (cTnI) before (preop)
and 1, 6, 12, 24, 48, and 72 hours after coronary artery bypass grafting
(mean  standard deviation) with (black circles, n ¼ 12) or without
(open circles, n ¼ 12) remote ischemic preconditioning (RIPC) under
propofol anesthesia.
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Danesthesia; or (2) no increased STAT5 phosphorylation occurs with RIPC
during propofol anesthesia.
RESULTS
A total of 35 patientswith 3-vessel coronary artery disease
were initially screened from June 2010 toDecember 2011, of
whom 29were eligible for study enrollment. Six of these pa-
tientswere ineligible for enrollment because of diabetesmel-
litus. All 29 patients agreed to participate and were
randomized to receive RIPC or no RIPC under propofol an-
esthesia. After randomization, 5 additional patients had to be
excluded. In 4 patients, the protein yield from a LV biopsy
was insufficient and 1 patient was withdrawn because of an
unclear biopsy assignment to baseline or reperfusion.
Accordingly, the data from 24 patients (21 men and 3
women; mean age, 66 years; range, 53-80 years; weight,
84.9  3 kg, height, 174  7 cm), who had undergone pro-
pofol anesthesia with either RIPC (n ¼ 12) or no RIPC
(n ¼ 12), were analyzed.
The characteristics of the study cohorts are listed in
Table 1. No differences were found between the cohorts378 The Journal of Thoracic and Cardiovascular Surgin patient characteristics or intraoperative data, such as total
anesthesia time, CPB and crossclamp times, inotropic sup-
port at the end of surgery, cardioplegia volume adminis-
tered, or in-hospital mortality. Although the same number
of patients in each group received b-blockers, more patients
in the RIPC than in the no RIPC group took calcium channel
blockers.
RIPC During Propofol Anesthesia
The preoperative cTnI level did not differ between the 2
groups (P ¼ .10). RIPC did not significantly alter the cTnI
AUC (RIPC, 273  184 ng/mL 3 72 hours; no RIPC,
365  301 ng/mL 3 72 hours; P ¼ .374); cTnI at 1
(P ¼ .72), 6 (P ¼ .45), 12 (0.68), 24 (P ¼ .35), 48
(P ¼ .19), and 72 (P ¼ .15) hours after CABG surgery; or
individual peak cTnI (RIPC, 11.7  9.2 ng/mL; no RIPC,
11.6  8.3 ng/mL, P ¼ .988; Figure 1). With an
intention-to-treat analysis of all patients subjected to the
randomized protocol (n ¼ 29), RIPC also did not alter the
cTnI AUC (RIPC [n ¼ 15], 285  201 ng/mL 3 72 hours;
no RIPC [n¼ 14], 330 290 ng/mL3 72 hours; P¼ .352).
Protein Phosphorylation With and Without RIPC
The concentration of total proteins did not differ signifi-
cantly between the 2 groups, either at baseline or after re-
perfusion (Table 2). Likewise, the concentration of
phosphorylated proteins did not differ between the 2 groups
at baseline (Table 3).
The phosphorylation of p38, protein kinase B, extracellu-
lar signal-regulated kinase 1/2, p70 ribosomal S6 protein ki-
nase, glycogen synthase kinase 3b, and STAT3 at tyrosine
705 and serine 727 was significantly increased from base-
line to early reperfusion but was not different between
groups with and without RIPC. STAT5 phosphorylation
was not increased from baseline to early reperfusion in pa-
tients with and without RIPC (Table 2). This lack of effect in
STAT5 phosphorylation was confirmed with 2 different
antibodies (Figure 2).ery c January 2014
TABLE 2. Total protein levels during baseline and reperfusion, with and without RIPC
Variable
Total protein/Ponceau staining
RIPC No RIPC
Baseline Reperfusion P value Baseline Reperfusion P Value
PKCa 1.10  0.145 1.21  0.078 .35 0.96  0.116 1.05  0.174 .67
p38 0.43  0.074 0.54  0.080 .24 0.83  0.071 0.98  0.126 .16
VASP 0.55  0.060 0.81  0.159 .09 0.94  0.080 1.10  0.159 .26
eNOS 1.42  0.338 0.77  0.211 .11 0.47  0.072 0.48  0.065 .84
AKT 1.14  0.142 0.98  0.141 .13 0.61  0.081 0.63  0.092 .78
ERK1/2 0.42  0.077 0.38  0.067 .67 0.65  0.065 0.76  0.095 .10
p70S6K 0.40  0.062 0.48  0.102 .57 0.49  0.079 0.47  0.076 .68
GSK3b 0.66  0.071 0.61  0.088 .62 0.43  0.061 0.39  0.057 .56
STAT3tyr 1.07  0.134 1.17  0.165 .49 0.53  0.082 0.63  0.099 .11
STAT3ser 0.47  0.054 0.55  0.096 .45 0.53  0.093 0.52  0.105 .83
STAT5 A 0.71  0.076 0.78  0.085 .43 0.61  0.081 0.71  0.100 .71
STAT5 B 0.93  0.098 0.97  0.086 .49 0.88  0.080 0.81  0.061 .45
Baseline Reperfusion
RIPC No RIPC RIPC No RIPC
PKCa 0.79  0.082 0.93  0.138 .47 0.45  0.045 0.59  0.086 .17
p38 0.80  0.083 1.02  0.116 .34 0.71  0.056 0.73  0.105 .88
VASP 0.45  0.054 0.59  0.087 .23 0.68  0.130 0.68  0.156 .99
eNOS 0.71  0.086 0.70  0.109 .94 0.41  0.044 0.51  0.055 .18
AKT 0.93  0.059 0.85  0.106 .51 0.59  0.044 0.63  0.072 .66
ERK1/2 0.68  0.072 0.65  0.088 .72 0.58  0.063 0.58  0.105 .98
p70S6K 0.55  0.045 0.46  0.058 .32 1.27  0.166 1.53  0.221 .36
GSK3b 0.78  0.083 0.81  0.083 .85 1.47  0.131 1.68  0.176 .34
STAT3tyr 0.86  0.079 0.75  0.101 .32 0.66  0.052 0.72  0.093 .53
STAT3ser 0.76  0.060 0.68  0.081 .49 1.33  0.113 1.50  0.198 .46
STAT5 A 0.53  0.094 0.62  0.110 .52 0.83  0.120 0.79  0.097 .77
STAT5 B 0.34  0.046 0.41  0.070 .43 0.73  0.110 0.71  0.076 .88
Baseline and reperfusion data are derived from separate gels and differ between upper and lower portions of table. Statistical comparisons made only for data from same gel.
Ponceau staining used to normalize for protein loading of gels. RIPC, Remote ischemic preconditioning; PKCa, protein kinase Ca; p38, p38 mitogen-activated protein kinase;
VASP, vasodilator-stimulated phosphoprotein; eNOS, endothelial nitric oxide synthase; AKT, protein kinase B; ERK, extracellular signal-regulated kinase; p70S6K, p70 ribosomal
S6 protein kinase; GSK3b, glycogen synthase kinase-3b; STAT, signal transducer and activator of transcription; tyr, tyrosine; ser, serine.
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DDISCUSSION
In the present randomized, single-blind, placebo-con-
trolled, prospective study, we have confirmed, in another
cohort of nondiabetic patients undergoing elective CABG,
the lack of cardioprotection by RIPC under propofol anes-
thesia that we previously reported.13 Furthermore, in con-
trast to the cardioprotection obtained by RIPC, along with
STAT5 activation under isoflurane anesthesia,14 no STAT5
activation occurred under propofol anesthesia. This absence
under propofol anesthesia of both cardioprotection and
STAT5 activation confirms, not only that propofol somehow
interferes with RIPC-mediated protection but also might
suggest that this interference is located upstream of
STAT5 activation.
Study Limitations
It is important to note that positive controls for a study
such as the present one are needed. However, we have
previously published 2 positive controls. We reported
that STAT5 phosphorylation is increased in patientsThe Journal of Thoracic and Caundergoing CABG with previous RIPC14 and also that
protection by RIPC is achieved during isoflurane, but
not during propofol, anesthesia.13 Given that propofol de-
prived patients of cardioprotection and that the analysis of
STAT5 phosphorylation required LV biopsies, we did
not repeat these positive controls just for additional
confirmation.
None of the proteins previously implicated in cardiopro-
tection was different with RIPC, except for STAT5 with
isoflurane anesthesia. Potassium-adenosine triphosphate
mitochondrial channels have been implicated in the mech-
anism of ischemic preconditioning.15,16 Mitochondrial
adenosine triphosphate-sensitive potassium channels were
not addressed in the present study, because their molecular
identity has not yet been defined. Therefore, they were not
amenable to protein analysis. The analysis of a role for mi-
tochondrial adenosine triphosphate-sensitive potassium
channels would require the use of specific agonists or antag-
onists, which was beyond the scope of the present study in
humans.rdiovascular Surgery c Volume 147, Number 1 379
TABLE 3. Activation of signaling proteins by phosphorylation
Phosphoprotein/total protein
RIPC No RIPC
Baseline Reperfusion P value Baseline Reperfusion P value
p-PKCa/b/PKCa 0.64  0.084 0.68  0.085 .62 0.79  0.059 0.86  0.052 .21
p-p38/p38 0.86  0.215 4.08  0.723 .004 1.20  0.430 2.20  0.249 .02
p-VASP/VASP 1.08  0.130 0.95  0.117 .41 0.52  0.065 0.51  0.073 .90
p-eNOS/eNOS 2.08  0.494 2.53  0.364 .50 2.85  0.582 2.15  0.383 .12
p-AKT/AKT 0.09  0.009 1.43  0.247 .00003 0.50  0.062 1.74  0.370 .01
p-ERK1/2/ERK1/2 1.40  0.335 3.31  0.470 .02 0.54  0.110 0.90  0.105 .04
p-p70S6K/p70S6K 0.31  0.050 3.13  0.605 .0001 0.26  0.064 1.84  0.174 .00001
p-GSK3b/GSK3b 0.54  0.081 1.31  0.089 .0000003 1.13  0.083 2.23  0.226 .001
p-STAT3tyr/STAT3 0.13  0.024 1.23  0.121 .0003 0.96  0.420 2.57  0.520 .03
p-STAT3ser/STAT3 0.77  0.079 2.38  0.260 .0002 0.54  0.045 2.18  0.381 .002
p-STAT5tyr/STAT5-A 0.80  0.119 0.87  0.165 .60 1.28  0.223 1.72  0.676 .52
p-STAT5tyr/STAT5-B 0.59  0.052 0.65  0.116 .55 0.87  0.129 0.93  0.145 .76
Baseline Reperfusion
RIPC No RIPC RIPC No RIPC
p-PKCa/b/PKCa 1.17  0.065 1.16  0.038 .92 1.37  0.074 1.14  0.119 .11
p-p38/p38 1.26  0.241 1.81  0.333 .18 1.04  0.168 1.03  0.104 .96
p-VASP/VASP 0.41  0.063 0.51  0.076 .30 0.59  0.114 0.47  0.060 .37
p-eNOS/eNOS 2.28  0.189 2.07  0.317 .55 0.87  0.214 1.27  0.311 .31
p-AKT/AKT 0.47  0.055 0.69  0.148 .17 0.80  0.133 0.70  0.139 .60
p-ERK1/2/ERK1/2 1.03  0.090 1.62  0.319 .09 0.63  0.114 0.77  0.132 .43
p-p70S6K/p70S6K 1.10  0.164 1.82  0.421 .11 1.35  0.242 1.03  0.151 .28
p-GSK3b/GSK3b 0.76  0.069 0.86  0.045 .23 0.82  0.104 0.85  0.071 .82
p-STAT3tyr/STAT3 0.37  0.042 0.68  0.178 .11 0.64  0.094 0.67  0.140 .87
p-STAT3ser/STAT3 1.27  0.095 1.32  0.131 .75 0.70  0.068 0.62  0.074 .45
p-STAT5tyr/STAT5-A 1.09  0.136 1.30  0.250 .48 0.82  0.167 0.81  0.213 .96
p-STAT5tyr/STAT5-B 1.15  0.143 1.38  0.131 .25 0.97  0.149 0.99  0.251 .95
Baseline and reperfusion data are derived from separate gels and differ between upper and lower portions of table. Statistical comparisons made only for data from same gel.
Ponceau staining used to normalize for protein loading of gels. RIPC, Remote ischemic preconditioning; PKCa, protein kinase Ca; p38, p38 mitogen-activated protein kinase;
VASP, vasodilator-stimulated phosphoprotein; eNOS, endothelial nitric oxide synthase; AKT, protein kinase B; ERK, extracellular signal-regulated kinase; p70S6K, p70 ribosomal
S6 protein kinase; GSK3b, glycogen synthase kinase-3b; STAT, signal transducer and activator of transcription; tyr, tyrosine; ser, serine.
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DInterpretation of Results
The present study is the first to report an association be-
tween a lack of RIPC effect and the lack of STAT5 activa-
tion, strengthening a causal role for STAT5 activation to
mediate the cardioprotective effect by RIPC, such as was
observed during isoflurane anesthesia.14 Previously, in-
creased STAT5 phosphorylation was reported in human
ischemic cardiomyopathy, but it was not related to function
or protection.17 In the present study, propofol appeared to
abolish, not only the cardioprotection evoked by RIPC,
known to occur during isoflurane anesthesia, but also
STAT5 activation. This supports the notion that STAT5 ac-
tivation might not only be associated with, but causally in-
volved in, cardioprotection.
Cardioprotection is highly complex and the cellular/sub-
cellular localization of STAT5 and its targets to effect cardi-
oprotection are currently unknown. However, we recently
demonstrated in a pig model of myocardial ischemia/reper-
fusion the activation of STAT3 by ischemic postcondition-
ing in mitochondria, along with better preservation of
mitochondrial respiratory function and calcium retention380 The Journal of Thoracic and Cardiovascular Surgcapacity.18 This STAT3 activation was in pigs and not in hu-
mans. Also, it was in response to ischemic postconditioning
and not to RIPC. Thus, we do not know whether the relative
roles of STAT3 and STAT5 relate to species differences or
differences in the conditioning protocols. The lipid-
soluble anesthetic agent propofol (2,6-diisopropylphenol)
has a chemical structure similar to that of phenol-based
free radical scavengers such as vitamin E19 but does not in-
teract with the adenosine triphosphate-sensitive potassium
channels in vitro.19 Because small amounts of reactive ox-
ygen species are necessary to evoke volatile anesthetic-
induced preconditioning,20 it is possible that propofol, by
eliminating such reactive oxygen species, interferes with
RIPC. Apparently, because propofol anesthesia was not as-
sociated with STAT5 activation and cardioprotection, it
might interfere with the signal transduction pathway of
RIPC somewhere upstream of STAT5.
The translation of cardioprotection to clinical routine is
clearly an issue, and age,21 comorbidities, and medications
are confounders.22,23 In our previous studies, the age and
medication characteristics of patients with coronary arteryery c January 2014
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FIGURE 2. Comparison of phosphorylated (p) and total signal transducer
and activator of transcription (STAT)5 content in left ventricular myocar-
dial biopsy specimens obtained from patients with coronary artery disease
undergoing remote ischemic preconditioning (RIPC) or not (no RIPC) un-
der propofol anesthesia. A, original Western blot; and B, C,
mean  standard deviation. tyr, Tyrosine.
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Ddisease did not appear to interfere with the cardioprotection
evoked by RIPC.1,6,13 To date, we also carefully excluded
those with diabetes from our mechanistic studies, because
diabetes interferes with cardioprotective signaling.24
b-Blockers might interfere with anesthesia-induced precon-
ditioning25; however, no such interference has been re-
ported for calcium channel blockers, the use of which
differed between the groups in our study. Of particular im-
portance are the anesthetic regimens, which have hardly
been standardized in RIPC trials and have usually have en-
tailed mixed various anesthetic regimens and dosages.9-11
Zaugg and colleagues,11 for instance, in their double-
blind, randomized, controlled trial used propofol and 3
different opioids (fentanyl, sufentanil, or remifentanil) for
induction and then isoflurane and 1 of the 3 opioids for
maintenance of anesthesia during CPB and reperfusion
and for the remainder of surgery. As noted in an editorial,12
this multitude of anesthetic variables raises the question of
whether different results might have been obtained if iso-
flurane and only 1 opioid had been given throughout the
induction of anesthesia, CPB, and reperfusion.
According to our previous data, propofol might interfere
with cardioprotective signaling. At the very least, we have
confirmed in a new cohort of patients that propofol is not as-
sociated with the degree of cardioprotection that has been
evoked by RIPC during isoflurane anesthesia in the same
setting (ie, a 50% reduction in accumulated postoperative
troponin I release). Taking LV biopsy specimens per se
did not increase the cTnI concentrations compared
with our previous data from patients under propofol
without LV biopsy specimens (RIPC with LV biopsies,The Journal of Thoracic and Ca273  184 ng/mL 3 72 hours; RIPC without LV biopsies,
290  175 ng/mL 3 72 hours, P ¼ .45; no RIPC with LV
biopsies, 365  301 ng/mL 3 72 hours; RIPC without LV
biopsies, 324  210 ng/mL 3 72 hours, P ¼ .41).13
Future studies are needed to assess whether RIPC not
only decreases troponin concentrations as a surrogate
marker of myocardial ischemia/reperfusion injury, but
also improves the clinical outcome of patients undergoing
coronary revascularization, and possibly also concomitant
valve surgery. A quantitative estimate suggested that only
patients with an infarct size of more than 20% of the left
ventricle and with a magnitude of infarct size reduction
from 75% to less than 40% of the area at risk would
have a prognostic benefit.26 The Effect of Remote Ischae-
mic preConditioning on clinical outcomes in patients un-
dergoing Coronary Artery Bypass Graft surgery
(ERICCA) trial, a multicenter, randomized, double-blind,
controlled, clinical trial, is underway to address this issue.27
The ERICCA trial has been scheduled to recruit in 27 ter-
tiary centers within 2 years a total of 1610 high-risk patients
undergoing CABG plus valve surgery using blood cardio-
plegia. However, the anesthetic regimen was not defined.
Thus, taking together our data from the present and previous
studies,1,13,14 although isoflurane permits cardioprotection
to be recruited by RIPC,28 propofol does not and might
even actively interfere with the cardioprotective signaling
of RIPC. Propofol appears to be a common denominator
of all published clinical studies that reported no protection
by RIPC.29 Our ultimate goal is to replace or enhance the
cardioprotective effects of RIPC using a pharmacologic car-
dioprotectant. STAT5 appears to be an important target for
such a cardioprotectant, and the potential abrogation of the
effects of RIPC by propofol might help to identify such
a cardioprotective agent.
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